The effect of fibrates on lowering low-density lipoprotein cholesterol and cardiovascular risk reduction: a systemic review and meta-analysis
European Journal of Preventive Cardiology · 15.02.2024 · 31 (3) · 291-301
DOI: 10.1093/eurjpc/zwad331 ↗Kurz gefasst
Metaanalyse in der Zeitschrift European Journal of Preventive Cardiology, online erschienen am 19.10.2023. Verfasst von Kyung An Kim und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiology, Department of Internal Medicine, Seoul St.Mary's Hospital, The Catholic University of Korea, 222 Banpo-daero, Seocho-gu, Seou…. Hauptthemen laut MEDLINE: Cardiovascular Diseases, Fibric Acids, Hypolipidemic Agents, Cholesterol, LDL. Die Arbeit wurde bisher 38-mal zitiert (Crossref) und nennt 35 Literaturangaben.
Abstract (Originalsprache)
Aims
The effect of fibrate treatment on cardiovascular risk is inconsistent. This meta-analysis aimed to assess the effect of fibrates on major adverse cardiovascular outcome (MACE) reduction. Methods and results PubMed, Embase, and Cochrane library databases were searched up to February 2023 for randomized controlled trials comparing fibrate therapy against placebo and reporting cardiovascular outcomes and lipid profile changes. The primary outcome was the clinical outcomes of each trial that most closely corresponding to MACE, a composite of cardiovascular death, acute myocardial infarction, stroke, and coronary revascularization. A pre-specified meta-regression analysis to examine the relationship between the changes in lipid levels after fibrate treatment and the risk of MACE was also performed. Twelve trials were selected for final analysis, with 25 781 patients and 2741 MACEs in the fibrate group and 27 450 patients and 3754 MACEs in the control group. Overall, fibrate therapy was associated with decreased risk of MACE [RR 0.87, 95% confidence interval (CI) 0.81–0.94] with moderate heterogeneity (I2 = 47%). In meta-regression analysis, each 1 mmol/L reduction in low-density lipoprotein cholesterol (LDL-C) after fibrate treatment reduced MACE (RR 0.71, 95% CI 0.49–0.94, P = 0.01), while triglyceride level changes did not show a significant association (RR per 1mmol/L reduction 0.96, 95% CI 0.53–1.40, P = 0.86). A sensitivity analysis with the composite outcome of cardiovascular death or acute myocardial infarction produced similar results.
Conclusion
Treatment with fibrates was associated with decreased risk of MACE. The reduction in MACE risk with fibrate therapy appears to be attributable to LDL-C reduction rather than a decrease in triglyceride levels.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Cardiology, Department of Internal Medicine, Seoul St.Mary's Hospital, The Catholic University of Korea, 222 Banpo-daero, Seocho-gu, Seoul 06591, Republic of Korea.
- Medical Library, The Catholic University of Korea, 222 Banpo-daero, Seocho-gu, Seoul 06591, Republic of Korea.
ORCID-Profile: Eun Ho Choo
Zitieren
APA
Kim, K. A., Kim, N. J., & Choo, E. H. (2024). The effect of fibrates on lowering low-density lipoprotein cholesterol and cardiovascular risk reduction: a systemic review and meta-analysis. European Journal of Preventive Cardiology, 31(3), 291-301. https://doi.org/10.1093/eurjpc/zwad331
Vancouver
Kim KA, Kim NJ, Choo EH. The effect of fibrates on lowering low-density lipoprotein cholesterol and cardiovascular risk reduction: a systemic review and meta-analysis. European Journal of Preventive Cardiology. 2024;31(3):291-301. doi:10.1093/eurjpc/zwad331
BibTeX
@article{Kim2024,
author = {Kim, Kyung An and Kim, Na Jin and Choo, Eun Ho},
title = {The effect of fibrates on lowering low-density lipoprotein cholesterol and cardiovascular risk reduction: a systemic review and meta-analysis},
journal = {European Journal of Preventive Cardiology},
year = {2024},
volume = {31},
number = {3},
pages = {291--301},
doi = {10.1093/eurjpc/zwad331}
}
EUVIMED